ALDH+ Cancer Precursor Cells in Drug Response Prediction
Mr. Ed Field, Chief Operating Officer at Aldagen, explains the principles behind ALDEFLUOR™-based detection of ALDH bright cells and discusses evidence demonstrating ALDH’s potential as a biomarker for cancer stem cell characterization and tumor prognosis.
Publish Date: September 09, 2009
Publish Date: September 06, 2011
Publish Date: May 27, 2011